Kong, Y. W., Vogrin, S., Ekinci, E., Taylor, P., O’Neal, D. N., Jenkins, A., . . . Fenn, J. Rationale and design of a randomised phase II multicentre crossover trial investigating a sodium-glucose co-transporter 2 inhibitor, dapagliflozin, combined with a novel continuous ketone monitor in adults with type 1 diabetes to reduce the risk of diabetic ketoacidosis: The PARTNER study. BMJ Publishing Group.
Chicago Style (17th ed.) CitationKong, Yee Wen, et al. Rationale and Design of a Randomised Phase II Multicentre Crossover Trial Investigating a Sodium-glucose Co-transporter 2 Inhibitor, Dapagliflozin, Combined with a Novel Continuous Ketone Monitor in Adults with Type 1 Diabetes to Reduce the Risk of Diabetic Ketoacidosis: The PARTNER Study. BMJ Publishing Group.
MLA (9th ed.) CitationKong, Yee Wen, et al. Rationale and Design of a Randomised Phase II Multicentre Crossover Trial Investigating a Sodium-glucose Co-transporter 2 Inhibitor, Dapagliflozin, Combined with a Novel Continuous Ketone Monitor in Adults with Type 1 Diabetes to Reduce the Risk of Diabetic Ketoacidosis: The PARTNER Study. BMJ Publishing Group.